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Beneficial Endocrine but Adverse Exocrine Effects of
Sitagliptin in the Human Islet Amyloid Polypeptide
Transgenic Rat Model of Type 2 Diabetes
Interactions With Metformin
Aleksey V. Matveyenko,1 Sarah Dry,2 Heather I. Cox,1 Artemis Moshtaghian,1 Tatyana Gurlo,1
Ryan Galasso,1 Alexandra E. Butler,1 and Peter C. Butler1
OBJECTIVE—We sought to establish the extent and mecha-
nisms by which sitagliptin and metformin singly and in combi-
nation modify islet disease progression in human islet amyloid
polypeptide transgenic (HIP) rats, a model for type 2 diabetes.
RESEARCH DESIGN AND METHODS—HIP rats were treated
with sitagliptin, metformin, sitagliptin plus metformin, or no drug
as controls for 12 weeks. Fasting blood glucose, insulin sensitiv-
ity, and -cell mass, function, and turnover were measured in
each group.
RESULTS—Sitagliptin plus metformin had synergistic effects to
preserve -cell mass in HIP rats. Metformin more than sitagliptin
inhibited -cell apoptosis. Metformin enhanced hepatic insulin
sensitivity; sitagliptin enhanced extrahepatic insulin sensitivity
with a synergistic effect in combination. -Cell function was
partially preserved by sitagliptin plus metformin. However, sita-
gliptin treatment was associated with increased pancreatic duc-
tal turnover, ductal metaplasia, and, in one rat, pancreatitis.
CONCLUSIONS—The combination of metformin and sitagliptin
had synergistic actions to preserve -cell mass and function and
enhance insulin sensitivity in the HIP rat model of type 2
diabetes. However, adverse actions of sitagliptin treatment on
exocrine pancreas raise concerns that require further evaluation.
Diabetes 58:1604–1615, 2009
The prevalence of type 2 diabetes and the associ-ated morbidity and mortality are increasing (1).There is therefore interest in strategies to slowor prevent the development of type 2 diabetes.
Although insulin resistance secondary to lifestyle changes
likely contributes to the increased prevalence, most insu-
lin-resistant individuals increase insulin secretion and
remain nondiabetic (2). In contrast, in those genetically
vulnerable to develop type 2 diabetes, -cell function fails
to appropriately adapt to insulin resistance, leading to
hyperglycemia (3,4).
Prospective studies in humans have reported a progres-
sive decline in -cell function preceding development of
type 2 diabetes (5,6). Autopsy studies reveal that the islet
in type 2 diabetes is characterized by a 60% deficit in
-cells and islet amyloid derived from islet amyloid
polypeptide (IAPP), a 37–amino acid peptide cosecreted
with insulin by -cells (7). The cause of the defect in -cell
mass in type 2 diabetes remains unresolved but is likely
attributable, at least in part, to endoplasmic reticulum
stress–induced -cell apoptosis, noted both at autopsy and
in isolated islets from people with type 2 diabetes (8,9).
Based on these observations, it is apparent that to favor-
ably modify disease progression in type 2 diabetes, pres-
ervation of -cell mass and function in the setting of
insulin resistance is required.
Our primary objective in the current study was to test
the hypothesis that the combination of two potentially
synergistic therapies, the dipeptidyl peptidase-4 (DPP-4)
inhibitor sitagliptin and hepatic insulin sensitizer met-
formin, modify progression of islet dysfunction and loss of
-cell mass in type 2 diabetes. Because it is not possible to
evaluate -cell mass or turnover in vivo in humans, we
undertook these studies in the human IAPP transgenic
(HIP) rat because it approximates the islet and metabolic
phenotype of type 2 diabetes in humans (10–12).
Metformin has previously been shown to delay onset of
type 2 diabetes (13). Glucagon-like peptide 1 (GLP-1) has
reversed loss of -cell mass in some murine models of
diabetes by both increasing new -cell formation and
decreasing -cell apoptosis (14–16). The DPP-4 inhibitor
sitagliptin increases GLP-1 concentrations (17) and mod-
estly lowers glucose levels when used alone in type 2
diabetes (18,19) with an additive effect in combination
with metformin (20,21).
Therefore, we sought to address the following ques-
tions. First, do metformin or sitagliptin individually or in
combination favorably modify disease progression (reduc-
ing -cell loss and dysfunction) at the level of the islet in
the HIP rat model of type 2 diabetes? Second, is any
protection of -cell mass accomplished by decreased
-cell apoptosis and/or increased -cell formation? Third,
what are the respective actions of these drugs on insulin
sensitivity and secretion singly, and in combination, in this
model of type 2 diabetes? Unexpectedly, we encountered
marked ductal metaplasia in 25% of high-fat diet–fed HIP
rats treated with sitagliptin and severe hemorrhagic pan-
creatitis in one sitagliptin-treated animal. Because those
From the 1Larry Hillblom Islet Research Center, Division of Endocrinology,
David Geffen School of Medicine, University of California Los Angeles, Los
Angeles, California; and the 2Department of Pathology and Laboratory
Medicine, David Geffen School of Medicine, University of California Los
Angeles, Los Angeles, California.
Corresponding author: Aleksey Matveyenko, amatveyenko@mednet.ucla.ed.
Received 12 January 2009 and accepted 8 April 2009.
Published ahead of print at http://diabetes.diabetesjournals.org on 29 April
2009. DOI: 10.2337/db09-0058.
© 2009 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for profit,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
1604 DIABETES, VOL. 58, JULY 2009
findings have potentially important clinical implications,
we evaluated the exocrine effects of sitagliptin. These
latter studies provided some insights into the reported
association of GLP-1 mimetic therapy by exenatide (22)
or liraglutide (23) and pancreatitis, and they provide
some cautions about the potential long-term effects of
GLP-1 mimetic therapy, including DPP-4 inhibition in
diabetes.
RESEARCH DESIGN AND METHODS
A total of 40 Sprague-Dawley rats (wild type; n  7) and rats expressing
human IAPP (HIP rats; n  33) were used in the current study. Generation of
HIP rats has been described in detail previously (11). Rats were bred and
housed individually throughout the study at the University of California Los
Angeles animal housing facility and subjected to standard 12-h light/dark
cycle. The University of California Los Angeles institutional animal care and
use committee approved all surgical and experimental procedures. To estab-
lish the actions of sitagliptin and metformin singly and in combination on islet
protection, 2-month-old wild-type and HIP rats were fed high-fat diet ad
libitum for 12 weeks (60% fat, 20% protein, and 20% carbohydrates; no. D12492;
Research Diets, New Brunswick, NJ) and randomly assigned into five inde-
pendent treatment groups: wild-type rats (no drug treatment, n  7), HIP rats
(no drug treatment, n  8), HIP rats given sitagliptin (200 mg  kg body wt1 
day1 sitagliptin, n  8), HIP rats given metformin (200 mg  kg body wt1 
day1 metformin, n  9), and HIP rats given sitagliptin plus metformin (200
mg  kg body wt1  day1 sitagliptin and metformin, n  8). Sitagliptin was
provided by Merck Research (Rahway, NJ), and metformin was purchased
from Toronto Research Chemicals (Toronto, Canada). Compounds were
administered after premixing with high-fat diet, which was performed by
Research Diets. After 12 weeks of diet/drug treatment, animals were anesthe-
tized with isoflourane (2.5%) by inhalation until effect (Isoflourane Vapor 19.1;
Summit Anesthesia, Portland, OR). Indwelling catheters were then inserted
into the right internal jugular vein and left carotid artery for subsequent in vivo
metabolic studies, as previously described (24). All catheters were filled with
100 units/ml heparin/saline solution, exteriorized to the back of the neck, and
encased in the infusion harness (Instech, Plymouth Meeting, PA).
Hyperglycemic clamp and arginine bolus injection. To assess glucose-
and arginine-stimulated insulin secretion, wild-type rats (n 6), HIP rats (n
8), HIP rats given sitagliptin (n  8), HIP rats given metformin (n  6), and
HIP rats given sitagliptin plus metformin (n  6) underwent a hyperglycemic
clamp followed by an arginine bolus injection, as previously described (10). In
brief, after a 30-min equilibration period (30 to 0 min), plasma samples were
taken for measurements of baseline fasting glucose and insulin. Thereafter,
animals received an intravenous glucose bolus (375 mg/kg) followed by a
variable 50% (wt/vol) glucose infusion to clamp arterial glucose at 250 mg/dl
(0–70 min). At t 60 min, rats received a bolus injection of L-arginine solution
(1 mmol/kg; Sigma, St. Louis, MO). Arterial blood samples (50 l) were taken
at baseline (30 and 0 min), at 1 and 5 min, and every 15 min thereafter during
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FIG. 1. Fasting plasma glucose (A), body weight (B), mean daily food intake (C), and mean daily drug consumption (D) after 12-week treatment
with 60% high-fat chow diet in wild-type (WT) rats (n  7), HIP rats (n  8), HIP rats treated with sitagliptin (HIPSIT; n  8), HIP rats treated
with metformin (HIPMET; n  9), and HIP rats treated with combination therapy (HIPSITMET; n  8). Data are means  SE.
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the clamp for immediate determination of plasma glucose and subsequent
analysis for insulin.
Hyperinsulinemic-euglycemic clamp and 3H-glucose infusion. To assess
insulin sensitivity and glucose turnover, wild-type rats (n  5), HIP rats
(n  6), HIP rats given sitagliptin (n  7), HIP rats given metformin (n 
6), and HIP rats given sitagliptin plus metformin (n  6) underwent a
hyperinsulinemic-euglycemic clamp with concomitant infusion of
[3-3H]glucose to assess glucose turnover, as previously described (10).
Briefly, rats received primed (3 Ci) continuous (0.05 Ci/min) infusion of
[3-3H]glucose (Perkin Elmer, Boston, MA) for a 90-min basal period that
increased to 0.2 Ci/min for 120 min throughout the hyperinsulinemic-
euglycemic clamp, which was achieved by constant infusion of regular
human insulin (Novolin; Novo Nordisk, Princeton, NJ) at 4 mU  kg1 
min1, variable glucose (50% wt/vol) infusion, and somatostatin infusion
(10 g  kg1  min1; Bachem, CA) to inhibit endogenous insulin secretion.
Plasma glucose levels were determined every 10 min, and additional blood
samples (100 l) were collected at baseline (30 min) and at the end of
the clamp for determination of plasma insulin. Blood samples (150 l) for
determination of tracer-specific activity were drawn at fasting (from – 40 to
0 min) and during insulin infusion.
Endocrine pancreas histology. Rats were killed by 120 mg/kg i.v. sodium
pentobarbital. The pancreas was then rapidly removed from killed rats and
fixed in 4% paraformaldehyde overnight at 4°C. Paraffin-embedded pancreatic
sections were stained first for hematoxylin/eosin and insulin (guinea pig
anti-insulin, 1:100; Zymed, Carlsbad, CA). The -cell mass was measured by
first quantifying the pancreatic fractional area positive for insulin and multi-
plying this by the pancreatic weight. In addition, sections were costained by
immunofluorescence for insulin (guinea pig anti-insulin, 1:100; Zymed, Carls-
bad, CA) and terminal deoxynucleotidyl transferase biotin-dUTP nick-end
labeling (TUNEL) method (Roche Diagnostics, Mannheim, Germany) for
quantification of -cell apoptosis, and they were costained for insulin (guinea
pig anti-insulin, 1:100; Zymed) and Ki-67 (mouse anti–Ki-67, 1:50; Dako,
Carpinteria, CA) for determination of -cell replication. All -cells per
pancreatic section (2,500 cells per section) were examined in detail and
counted at 200 magnification (20 objective, 10 ocular) for the total
number of TUNEL- and Ki-67–positive -cells. The frequency of TUNEL and
Ki-67 was presented as the percentage of total -cells per section.
Fluorescent slides were analyzed and imaged using a Leica microscope
(Leica Microsystems, Wetzlar, Germany) and images acquired using Open-
Lab microscope software (Improvision) and analyzed using ImagePro Plus
software.
Exocrine pancreas histology. Pancreas sections were deparaffinized in
xylene and rehydrated in ethanol gradient, and pancreatic sections were
stained in Harris hematoxylin solution (HHS16; Sigma) and eosin Y solution
(HT110132; Sigma). For immunofluorescence, antigen retrieval was per-
formed via microwave heating in citrate buffer (H-3300; Vector, Burlingame,
CA) except for TUNEL staining, which used proteinase-K digestion (V302B;
Promega, Madison, WI) at 37°C for 15 min. Slides were blocked in Tris-
buffered saline (3% BSA, 0.2% TX-100, and 2% donkey serum) for 1 h. The
following primary antibodies were used for 12-h incubation: ductal cell
marker cytokeratin (mouse anti-pancytokeratin, 1:50; Sigma), marker of cell
fibrosis fibrinectin (rabbit anti-fibrinectin, 1:500; Sigma), replication marker
Ki-67 (mouse anti–Ki-67, 1:50; Dako), apoptosis marker (TUNEL method;
Roche Diagnostics), marker of T-cell infiltration (rabbit anti-CD3; Abcam,
Cambridge, MA), marker of macrophage infiltration (rabbit anti–CD-11C;
Abcam), GLP-1 receptor (rabbit anti–GLP-1 receptor, 1:100; Novus Biologi-
cals, Littleton, CO), pancreatic and duodenal homeobox 1 (PDX-1) (rabbit
anti–PDX-1, 1:1,000; Millipore, St. Louis, MO), and insulin (guinea pig anti-
insulin, 1:100; Zymed). Secondary antibodies labeled with Cy3 and fluorescein
isothiocyanate were obtained from Jackson Laboratories (West Grove, PA)
and used at dilutions of 1:200 for 1-h incubation. To determine ductal cell
replication and apoptosis, in each pancreatic section we quantified the
total number of Ki-67–, TUNEL-, and cytokeratin-positive cells (1,000
cytokeratin-positive cells per section were counted). The frequency of
ductal cell replication and apoptosis in each animal was presented as a
total number of TUNEL- or Ki-67–positive cells per total number of
cytokeratin-positive cells.
Analytical procedures. Plasma glucose concentrations were measured by
the glucose oxidase method (Glucose Analyzer 2; Beckman, Fullerton, CA).
Plasma insulin was measured using competitive colorimetric enzyme-linked
immunosorbent assay (Alpco Diagnostics, Salem, NH). Plasma glucose spe-
cific activity, hepatic glucose production, and glucose disposal was calculated
as previously described in detail (10). Disposition index was calculated as the
product of first-phase insulin secretion during the hyperglycemic clamp
Insulin/Hematoxylin Insulin/Hematoxylin
Insulin/Hematoxylin Insulin/Hematoxylin
0
10
20
30 P<0.05
P<0.05 vs. all groups
P<0.05
P<0.05
B
et
a-
ce
ll 
m
as
s 
(m
g)
0.0
0.5
1.0
1.5
2.0
WT
HIP
HIP+SIT
HIP+MET
HIP+SIT+MET
P<0.05
P<0.05
P<0.05 vs. all groups
B
et
a-
ce
ll 
ar
ea
(%
 p
os
it
iv
e 
fo
r 
in
su
lin
)
WT HIP
HIP+SIT HIP+SIT+MET
A B
C
FIG. 2. A: Typical islets from wild-type (WT) rats, HIP rats, HIP rats treated with sitagliptin (HIPSIT), and HIP rats treated with sitagliptin and
metformin (HIPSITMET) stained for insulin (pink) and hematoxylin (blue). -Cell area (B) and mean -cell mass (C) after 12-week
treatment with 60% high-fat diet in wild-type rats (n  7), HIP rats (n  8), HIP rats treated with sitagliptin (HIPSIT; n  8), HIP rats treated
with metformin (HIPMET; n  9), and HIP rats treated with combination therapy (HIPSITMET; n  8). Data are the means  SE. (A
high-quality digital representation of this figure is available in the online issue.)
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(expressed as pmol/l  min) and insulin sensitivity determined by mean
glucose infusion rates (expressed in mg  kg1  min1) required to maintain
euglycemia during the hyperinsulinemic-euglycemic clamp.
Statistical analysis. Statistical analysis was performed using ANOVA with
Fisher’s post hoc test where appropriate. Regression analysis was performed
using Statistica (version 6; Statsoft, Tulsa, OK). Data in graphs and tables are
the means  SE. Findings were assumed to be statistically significant at P 
0.05.
RESULTS
Blood glucose concentrations, body weight, and food
intake. Prior to initiation of high-fat diet, blood glucose
was comparable (105  4 mg/dl) in wild-type and HIP rats
(Fig. 1A). After 12 weeks of high-fat diet, plasma glucose
increased to 209 12 mg/dl in HIP rats but was unchanged
(108  3 mg/dl) in wild-type rats. Both metformin and
sitagliptin alone had a comparable effect on restraining
this increase in blood glucose concentration in HIP rats
(increased to 154  7 vs. 209  12 mg/dl, P  0.05),
whereas the combination of sitagliptin and metformin had
a synergistic effect (increased to 138  8 vs. 209  12
mg/dl, P  0.01). Weight gain on the high-fat diet was
comparable in wild-type (from 312 5 to 628 30 g) (Fig.
1B) and untreated HIP rats (from 291  10 to 639  14 g)
(Fig. 1B) but was 10% less in either sitagliptin- or
metformin-treated HIP rats (P  0.05) (Fig. 1B) and 15%
less in HIP rats treated with combination therapy (P 
0.05) (Fig. 1B). Food intake was decreased in HIP rats
treated with metformin (10%, P  0.05 vs. HIP) (Fig. 1C)
and with both metformin and sitagliptin (20%, P  0.05
vs. HIP) (Fig. 1C).
-Cell mass, replication, and apoptosis. -Cell mass
was 70% decreased in untreated HIP versus wild-type
rats on high-fat diet (8.4  1.3 vs. 25.6  2.1 mg, P  0.05)
(Fig. 2) as a consequence of increased -cell apoptosis, as
previously reported (12). Sitagliptin therapy alone led to
preservation of -cell mass compared with untreated HIP
rats (8.4  1.3 vs. 16.6  2.5 mg, P  0.01) (Fig. 2). In HIP
rats treated with metformin alone, -cell mass was not
significantly different from untreated HIP rats (8.4  1.3
vs. 11.6  1.3 mg, P  0.24 for HIP rats vs. HIP rats given
metformin) (Fig. 2), but those treated with combination
therapy of sitagliptin and metformin had even better
preservation of -cell mass than those treated with sita-
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FIG. 3. A: Examples of islets stained for insulin (pink) and replication marker Ki-67 (brown) and nuclear stain hematoxylin (blue) imaged at 20.
B: Frequency of -cell replication in wild-type (WT) rats (n  7), HIP rats (n  8), HIP rats treated with sitagliptin (HIPSIT; n  8), HIP rats
treated with metformin (HIPMET; n 9), and HIP rats treated with combination therapy (HIPSITMET; n 8). C: Examples of islets stained
for insulin (green) and apoptosis marker (TUNEL; red) and nuclear stain (DAPI; blue) imaged at 20. D: Frequency of -cell apoptosis in
wild-type rats (n  7), HIP rats (n  8), HIP rats treated with sitagliptin (n  8), HIP rats treated with metformin (n  9), and HIP rats treated
with combination therapy (n  8). Data are means  SE. *P < 0.05 vs. wild type, HIP, and HIP plus metformin. Arrows indicate examples of
insulin-positive Ki-67 and TUNEL-positive cells. (A high-quality digital representation of this figure is available in the online issue.)
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gliptin alone (8.4 1.3 vs. 19.7 2.4 mg, P 0.001 for HIP
rats vs. HIP rats given sitagliptin plus metformin) (Fig. 2).
The frequency of -cell replication quantified by Ki-67
was increased by sitagliptin alone (0.2  0.1 vs. 0.6  0.1%
for HIP rats vs. HIP rats given sitagliptin, P 0.05) (Fig. 3A
and B) and by combination therapy (0.2  0.1 vs. 0.5 
0.1% for HIP rats vs. HIP rats given sitagliptin plus met-
formin, P  0.05) (Fig. 3A and B). In contrast, metformin
alone had no discernable effect on -cell replication.
Sitagliptin treatment alone decreased the frequency of
-cell apoptosis in HIP rats by 55% (P  0.05) (Fig. 3C
and D). Metformin treatment alone was even more effec-
tive at decreasing -cell apoptosis in HIP rats (by 75%,
P  0.05) (Fig. 3C and D), whereas sitagliptin and met-
formin in combination had an action to suppress -cell
apoptosis that was comparable to that of metformin alone
(Fig. 3C and D).
Insulin sensitivity. The impact of metformin and/or
sitagliptin on insulin sensitivity was evaluated in HIP rats
by hyperinsulinemic-euglycemic clamp and the isotope
dilution technique. As expected, the high-fat diet induced
insulin resistance in both wild-type and HIP rats (Fig. 4).
Insulin sensitivity, assessed by the mean glucose infusion
rates during the hyperinsulinemic period, was enhanced
by either metformin (14.2  1.4 vs. 5.3  1.5 mg  kg1 
min1, P  0.001) (Fig. 4 and supplemental Table 1, which
is available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db09-0058/DC1) or
sitagliptin (11.4  1.7 vs. 5.3  1.5 mg  kg1  min1, P 
0.01) therapy alone compared with high-fat diet HIP rats,
and in combination they had a slight additive effect (15.6
1.1 vs. 5.3 1.5 mg  kg1  min1, P 0.001). In the fasting
state, isotopically measured hepatic glucose release was
approximately twofold greater in HIP versus wild-type rats
(9.7  1.4 vs. 5.1  1.3 mg  kg1  min1, P  0.05)
(supplemental Table 1). In contrast, metformin alone or in
combination with sitagliptin led to a 40% suppression of
fasting hepatic glucose release in HIP rats, whereas sita-
gliptin alone had no measurable effect on hepatic glucose
release in the fasting state in HIP rats (supplemental Table
1). With insulin stimulation during the hyperinsulinemic-
euglycemic clamp, hepatic glucose release in HIP rats was
suppressed minimally compared with wild-type rats (7 vs.
100% for HIP vs. wild-type, P  0.05) (supplemental Table
1), confirming marked hepatic insulin resistance. Met-
formin alone or in combination with sitagliptin partially
restored hepatic insulin sensitivity in HIP rats, as indicated
by60% suppression of hepatic glucose release during the
hyperinsulinemic clamp (supplemental Table 1). Insulin-
stimulated glucose disposal tended to be 30% higher in
all three drug-treated groups compared with nontreated
HIP rats. The slightly decreased weight gain in the met-
formin- and sitagliptin-treated HIP rats may have contrib-
uted to the increased insulin sensitivity with each of these
therapies.
-Cell function. Glucose-mediated insulin secretion (ex-
amined by hyperglycemic clamp) was markedly attenu-
ated in HIP compared with wild-type rats on a high-fat diet
(648 141 vs. 5,423 480 pmol/l  min, P 0.05) (Fig. 5A).
There was no significant enhancement of first-phase (Fig.
5A) or second-phase (data not shown) glucose-mediated
insulin secretion in HIP rats treated with sitagliptin or
metformin alone when considered independently of insu-
lin sensitivity. However, taking insulin sensitivity into
account in the calculated disposition index (Fig. 5B),
glucose-mediated insulin secretion in HIP rats was com-
parably enhanced by either metformin or sitagliptin alone,
and in combination these drugs had a synergistic action to
further enhance the disposition index (P  0.05 for HIP
rats vs. HIP rats given sitagliptin plus metformin) (Fig. 5B).
Glucose-potentiated arginine-stimulated insulin secretion
was also markedly attenuated in HIP versus wild-type
rats (3,077  528 vs. 8,809  1,179 pmol/l, P  0.05)
(Fig. 5C), and again there was no appreciable benefit
from either sitagliptin or metformin independently or in
combination on this metric (Fig. 5C), which is generally
considered a surrogate of -cell mass (25). It is there-
fore of interest to note that the glucose-potentiated
arginine-elicited first-phase insulin response did not
reflect -cell mass (Fig. 5D) in metformin- and/or sita-
gliptin-treated HIP rats.
Pancreatitis in an HIP rat treated with sitagliptin.
The focus on the exocrine actions of sitagliptin arose as a
consequence of an unexpected observation of marked
necrotizing pancreatitis in one of eight rats treated with
sitagliptin (Fig. 6 and supplemental Figs. 1 and 2). The
region of pancreatitis was apparent as a mass of 2 cm
and histologically characterized by hemorrhagic necrosis,
fibrosis, inflammatory cell infiltrate, and areas of ductal
metaplasia (supplemental Figs. 1 and 2) (26–30). Although
pancreatitis was present in 1 of 8 HIP rats treated with
sitagliptin, it was not detected in any of the 17 HIP rats not
treated with sitagliptin (Table 1) or any of the 89 HIP rat
pancreases reported previously (7,10,12). Given this unex-
pected finding, we evaluated all the pancreases from this
study for ductal metaplasia and increased ductal turnover,
characteristics frequently present in pancreatitis in hu-
mans (29–31).
Ductal metaplasia. Ductal metaplasia was present in a
total of three HIP rats treated with sitagliptin (Table 1).
One of the three sitagliptin-treated HIP rats with ductal
metaplasia also displayed marked pancreatitis (Table 1).
These regions of ductal metaplasia were located both
separate from and adjacent to islets of Langerhans (Fig. 7
and supplemental Fig. 3) and consisted of angulated
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tubular structures, interspersed fibrosis, and inflammatory
cells. In some areas these were adjacent to atrophic acinar
cells (Fig. 7 and supplemental Fig. 3). Ductal metaplasia
was immunoreactive for cytokeratin and Ki-67 (Fig. 8A),
indicating a high rate of cell turnover. Furthermore, meta-
plastic areas included numerous fibroblasts (by morphol-
ogy and fibrinectin immunoreactivity) (Fig. 8B) and were
absent of PDX-1 expression (Fig. 8C).
Ductal cell turnover. Ductal replication quantified by
Ki-67 immunoreactivity was increased fourfold in un-
treated diabetic HIP rats versus wild-type controls (0.6 
0.2 vs. 2.5  0.3%, P  0.05) (Figs. 9 and 10A). Sitagliptin
treatment led to an additional three-fold increase in the
frequency of ductal cell replication versus untreated HIP
rats (2.5  0.3 vs. 7.3  0.7%, P  0.05) (Figs. 9 and 10 and
supplemental Fig. 4) and a 12-fold increase compared with
wild-type rats. Intriguingly, metformin treatment abro-
gated the effects of sitagliptin on ductal cell proliferation
(7.3  0.7 vs. 1.4  0.6%, P  0.05 for HIP rats given
sitagliptin vs. HIP rats given sitagliptin plus metformin)
(Figs. 9 and 10A). The frequency of ductal replication was
positively correlated with fasting blood glucose concen-
tration, with an apparent continuum between wild-type
and HIP rats (Fig. 10C), with the sitagliptin-only–treated
group displaced to a higher slope (Fig. 10C). Addition of
metformin to sitagliptin restored the frequency of ductal
replication to the same relationship with fasting glucose
concentrations observed in rats not exposed to sitagliptin
(Fig. 10C).
GLP-1 receptor, PDX-1, and insulin expression in
exocrine ducts. As previously reported (32), GLP-1 re-
ceptors were expressed in pancreatic ducts, but with no
differences between treatment groups (supplemental Fig.
5). PDX-1– and insulin-positive ductal cells were observed
after sitagliptin treatment in HIP rats (supplemental Fig.
6A). Although most -cells were present within well-
defined islets, occasional individual -cells were present
scattered in the exocrine pancreas. These scattered -cells
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were approximately sixfold more abundant in sitagliptin-
treated compared with untreated HIP rats (P  0.05)
(supplemental Fig. 6B). Interestingly, the number of scat-
tered -cells was also increased in metformin-treated
animals, but not in animals that received combination
therapy of sitagliptin plus metformin.
A B
C D
*
FIG. 6. Necrotizing pancreatitis in a HIP rat treated with sitagliptin for 12 weeks. A: Representative image at 2 magnification of the exocrine
pancreas stained for hematoxylin and eosin from an HIP rat treated with sitagliptin for 12 weeks with necrotizing pancreatitis. Note partially
preserved lobular configuration of the exocrine pancreas; however, note the significant loss of acinar cell density and the widening of the septae
(arrow) as well as a complete loss of acinar cells in some areas (circle). B: Representative image at4 magnification. At this higher magnification,
septal fibrosis and inflammation (arrows) are better appreciated as well as partial and complete loss of acinar cells (circle). C: Representative
image at 20 magnification. At this magnification, acinar cell injury and angulated tubular ductal structures within the acini are clearly seen
(circle). Note the extensive septal inflammation and fibrosis (*). D: Representative image at 40 magnification. At this higher magnification,
angulated tubular ductal structures and surrounding tissue fibrosis are better appreciated. (A high-quality digital representation of this figure
is available in the online issue.)
TABLE 1
Incidence of pancreatitis, ductal metaplasia, and increased ductal turnover by group
Wild type HIP HIP 	 SIT HIP 	 MET HIP 	 SIT 	 MET
Number studied 7 8 8 9 8
Pancreatitis 0 0 1 0 0
Ductal metaplasia 0 0 2 0 1
Increased ductal proliferation* — 4 8 2 1
Data are n. *Increase in ductal cell proliferation was defined as an increase in ductal proliferation 3 SDs above the mean of wild-type rats.
HIP 	 MET, HIP rats treated with metformin; HIP 	 SIT, HIP rats treated with sitagliptin; HIP 	 SIT 	 MET, HIP rats treated with
combination therapy.
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DISCUSSION
Our primary objective was to establish whether metformin
or sitagliptin alone and in combination favorably modified
disease progression in the HIP rat model of type 2 diabe-
tes. Although loss of -cell mass in the HIP rat was slowed
by this combination therapy, unexpected adverse actions
on the exocrine pancreas were also observed.
Metformin has been shown to delay type 2 diabetes
onset in humans (13). Because enhanced insulin sensitiv-
ity through lifestyle changes also delays diabetes (13), at
least part of the protective effect of metformin may be
mediated by metformin’s actions to enhance hepatic insu-
lin sensitivity through its actions on AMP-activated kinase
(33). Metformin decreased -cell apoptosis in isolated
human islets from patients with type 2 diabetes (34). In the
current study, metformin was more effective than sitaglip-
tin in reducing -cell apoptosis in the high-fat diet –fed HIP
rat. Although sitagliptin alone also suppressed -cell
apoptosis, there was no added benefit of sitagliptin on
metformin-mediated suppression of -cell apoptosis.
Sitagliptin enhanced -cell replication in HIP rats, consis-
tent with prior studies of GLP-1– and GLP-1 mimetic–
induced -cell replication in a variety of murine models
(14,15,32). The benefits of sitagliptin and/or metformin on
-cell mass and function reported here may have been
mediated by either direct effects of the drugs on -cells or
indirectly by their actions to lower blood glucose. Hyper-
glycemia can contribute to both loss of -cell mass by
increasing -cell apoptosis and/or loss of -cell function
(35). The current study was designed to examine effects of
sitagliptin and metformin treatment in an in vivo model of
type 2 diabetes, with the advantage of best approaching
actions in humans with type 2 diabetes, but with the
A B
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FIG. 7. Extensive ductal metaplasia in HIP rats treated with sitagliptin for 12 weeks. A and B: Representative images at 10 magnification of
ductal cell metaplasia observed in a rat treated with sitagliptin for 12 weeks. Metaplastic regions consisted of angulated tubular structures,
interspersed fibrosis, and inflammatory cells and were located both adjacent to islets of Langerhans (*) as well as separated from islets (circle).
C: Representative image at 20 magnification. At this higher magnification, an apparent transition from intact acinar cells to damaged/atrophic
acinar cells to angulated tubular ductal structures is seen. D: Representative image at 40 magnification. At this magnification the presence of
extensive angulated tubular ductal structures and surrounding tissue fibrosis within the metaplastic region is better appreciated. (A high-quality
digital representation of this figure is available in the online issue.)
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limitation of precluding distinction between direct and
indirect effects of drugs on -cell mass and function.
GLP-1–mediated increased -cell replication has to be
interpreted with caution. Juvenile rodents, in common
with juvenile humans, have a period of postnatal expan-
sion of -cell numbers mediated by -cell replication
(36,37). Such studies (including this one) in relatively
young rodents have exposed -cells to increased GLP-1
when they remain replication competent. Recent studies
have demonstrated that the capacity for new -cell forma-
tion through -cell replication is attenuated in adult ro-
dents after epigenetic modifications of -cells, and thus,
not surprisingly, older rodents do not exhibit the same
GLP-1–mediated -cell replication as that observed in
juvenile rodents (38,39). It is perhaps not surprising that
under conditions of increased GLP-1 secretion (post–
gastric bypass) in humans, despite earlier predictions (40),
neither -cell replication nor the fractional area of pan-
creas occupied by -cells was increased (41). Likewise,
long-standing exposure of nonhuman primates to the
GLP-1 mimetic exenitide was reported to not increase
-cell mass (42). Because the incremental effect of sita-
gliptin on metformin to preserve -cell mass in the current
study appeared to be mediated through its action to foster
-cell replication, it is possible that no such added benefit
would be present in humans.
The unexpected finding of hemorrhagic pancreatitis in
one of the sitagliptin-treated rats prompted further analy-
sis of the exocrine pancreas in this study. We report
increased ductal proliferation in all sitagliptin-treated rats
that were not also treated with metformin. We also noted
ductal metaplasia in three sitagliptin-treated rats, one of
which was also treated with metformin. Increased ductal
proliferation and ductal metaplasia are well-recognized
components of pancreatitis in humans (29–31), and they
therefore offer a plausible mechanism for the GLP-1–
induced pancreatitis reported in humans treated with the
GLP-1 mimetics exenatide or liraglutide (22,23). Ductal
GLP-1 receptor expression was not altered in any of the
treatment groups. It cannot be assumed that the actions of
sitagliptin to induce exocrine (or endocrine) pancreatic
changes are mediated through GLP-1 because other regu-
latory peptides are also degraded by DPP-4 (43). Further-
more, we cannot rule out direct actions of sitagliptin on
the exocrine pancreas. However, because pancreatitis has
also been reported in humans treated with GLP-1 agonists
(22,23), it seems likely that the exocrine effects of sitaglip-
tin treatment reported here are a consequence of in-
creased GLP-1 concentrations.
Perhaps of most concern, increased ductal cell turnover
and ductal metaplasia are also well-characterized risk
factors for pancreatic ductal cancer (31,44,45), as is pan-
creatitis (46). As yet, no increase in pancreatic cancer has
been reported in patients treated with GLP-1 mimetics or
DPP-4 inhibitors. However, these drugs have only been
available for a relatively short period of time. Any influ-
ence that GLP-1–based therapy might have to increase the
incidence of pancreatic cancer through chronically in-
creased ductal cell turnover would be expected to take
several years. The incidence of colon carcinoma associ-
ated with chronic epithelial replication and regeneration in
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FIG. 8. Extensive ductal metaplasia in sitagliptin-treated HIP rats is
characterized by increased ductal cell turnover, tissue fibrosis, and
absence of PDX-1 expression. A: Representative image at 20 magni-
fication of ductal cell metaplasia in an HIP rat treated with sitagliptin
for 12 weeks stained for ductal cell marker (cytokeratin; green),
replication marker (Ki-67; red), and nuclear stain (DAPI; blue). The
extent of ductal cell replication within metaplasia is highlighted by
coexpression of cytokeratin and Ki-67 immunoreactivity shown in the
insert. B: The same area of ductal metaplasia was stained for ductal
cell marker (cytokeratin; green), fibroblast marker (fibrinectin; red),
and nuclear stain (DAPI; blue). C: The same area of ductal cell
metaplasia stained for ductal marker (cytokeratin; green), PDX-1
(red), and insulin (blue). (A high-quality digital representation of
this figure is available in the online issue.)
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the setting of inflammation in ulcerative colitis starts to
increase 8–10 years after disease onset (47).
The current study may also shed some light on the
increased incidence of pancreatitis and pancreatic cancer
in patients with diabetes. Although pancreatitis or pancre-
atic cancer can lead to diabetes (48), epidemiological
studies imply that the converse may also be true (49–52).
Exocrine pancreatic insufficiency and pancreatitis are
common in both autoimmune-mediated type 1 and type 2
diabetes (48,53). In the current study, we noted increased
ductal turnover in the HIP rat related to plasma glucose
concentrations (Fig. 10C). This implies that hyperglycemia
per se may be sufficient to induce increased ductal cell
turnover. While controversial, it has been proposed that
there may be attempted -cell regeneration in diabetes
from progenitor cells that are proximate to, or within,
pancreatic ducts (54).
Moreover, it has been proposed that GLP-1–based ther-
apy enhances -cell formation by increasing -cell trans-
differentiation from these putative duct-related stem cells
(14,32). The action of sitagliptin treatment alone to in-
crease ductal replication, apparently still in a glucose-
sensitive manner but at a higher set point, is consistent
with a complimentary interaction between glucose and
GLP-1 concentrations to activate ductal cell proliferation.
The observed PDX-1– and insulin-positive ductal cells in
sitagliptin-treated HIP rats support this postulate.
An intriguing finding in the current study is the fact that
addition of metformin to sitagliptin prevented the sitaglip-
tin-mediated increase in ductal replication. Because met-
formin therapy has been shown to increase GLP-1 levels in
some studies (55), the action to counter sitagliptin-medi-
ated increased ductal replication is presumably indepen-
dent of GLP-1. It is possible that the effect was mediated
indirectly through metabolic actions of metformin to en-
hance insulin sensitivity or decrease blood glucose con-
centrations (56). Alternatively, metformin might act
directly on ductal cells to suppress proliferation. Antipro-
liferative effects of metformin have been reported in
prostate cancer cell lines and explanted prostate cells in
mice (57). Recent epidemiological studies have revealed
that metformin therapy is associated with a reduced
incidence of cancer, including pancreatic cancer (58). The
HIP+SIT
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FIG. 9. Ductal cell replication is increased in HIP rats treated with sitagliptin for 12 weeks. Representative images at 20 magnification of
exocrine ducts stained for cytokeratin (green), replication marker Ki-67 (red), and nuclear stain (DAPI; blue) in wild-type control rats, diabetic
HIP rats, HIP rats treated with sitagliptin, or HIP rats treated with combination therapy. *Examples from sitagliptin-treated rats represent
metaplasia and pancreatitis–free areas of the exocrine pancreas. Arrows indicate cytokeratin/Ki-67–positive cells. (A high-quality digital
representation of this figure is available in the online issue.)
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latter might be a consequence of the metabolic actions
and/or the direct antiproliferative effects of metformin.
It is unknown whether sitagliptin actions on ductal
turnover and/or induction of ductal metaplasia observed in
the HIP rat extends to humans. It is plausible that these
effects are restricted to the rat. It will be important to
address this in pancreata, when available, from humans
with type 2 diabetes who have been treated with GLP-1
mimetic therapy. Because the action of sitagliptin to
increase ductal turnover was dependent on hyperglyce-
mia, GLP-1 mimetic treatment on the exocrine pancreas in
nondiabetic animal models, as used in classical toxicology
screening studies, would presumably miss this effect and
its potential long-term adverse consequences.
In summary, sitagliptin, and metformin, had synergistic
effects on preserving -cell mass in the HIP rat model of
type 2 diabetes. Metformin was most effective at suppress-
ing -cell apoptosis. Sitagliptin fostered increased -cell
replication, but this is likely of limited benefit in adult
humans. Of concern, we noted pancreatitis in one, ductal
metaplasia in three and increased ductal turnover in all
sitagliptin-treated HIP rats. Because the apparent adverse
effects of GLP-1 mimetic therapy are at least to some
extent offset by concurrent use of metformin, it is perhaps
judicious to use GLP-1 mimetic therapy (including DPP-4
inhibiters) only in addition to metformin until potential
long-term adverse effects of GLP-1–based therapy on
exocrine pancreas can be ruled out in humans with
diabetes.
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